Live Update 
From the Liveblog of
Monday, August 23, 2021
From the Liveblog of
Monday, August 23, 2021
Pfizer to pay $2.26b for cancer treatment developer Trillium
Add ToI as a Preferred Source on GooglePfizer is spending more than $2 billion in cash to buy a drugmaker focused on cancer treatments.
Pfizer will pay $18.50 for each share of Trillium Therapeutics Inc., or more than double the stock’s 60-day weighted average price.
Trillium has no products on the market. Its potential treatments include biologics that aim to prime a patient’s immune system to detect and destroy cancer cells.
Its two lead candidates are in early-stage testing and focus on hematology. That includes blood, bone marrow and lymph node cancers like leukemia or lymphoma.
The deal will need approval from Trillium shareholders.
If you’d like to comment, join
The Times of Israel Community.
The Times of Israel Community.
JOIN THE TOI COMMUNITY
Already a member? Log in here